Combination therapy with GIP and GLP-1 enhances the incretin effect to improve dysglycaemia through increased prandial insulin secretion, reducing postprandial glycaemic excursions
Troubleshooting Low Entrapment Issues When formulations fail to meet target efficiency, our analytical services act as a diagnostic tool
Blood Sugar and Hemoglobin A1C Monitoring If you have prediabetes or type 2 diabetes, hemoglobin A1C (a 3-month average of blood glucose) is tracked every 3 months while on GLP-1 therapy
This test is distinct from pharmacogenomic testing and focuses on pathway biology rather than drug metabolism
ENERGY INCREASED - Carnitine promotes the conversion of fat into energy, providing you with an extra boost for your workouts and daily activities
The longest animal studies on BPC-157 span approximately 4 weeks to 12 weeks, leaving the safety profile for use extending beyond 3 months entirely undocumented in peer-reviewed literature